SVP, Head of Europe & Internat Pearce Samantha sale 531 shares of Jazz Pharmaceuticals plc [JAZZ]


The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Jazz Pharmaceuticals plc shares valued at $83,505 were sold by Pearce Samantha on Feb 02. At $157.26 per share, Pearce Samantha sold 531 shares. The insider’s holdings dropped to 11,309 shares worth approximately $1.63 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, COZADD BRUCE C sold 1,000 shares, netting a total of over 155,790 in proceeds. Following the sale of shares at $155.79 each, the insider now holds 367,078 shares.

Before that, COZADD BRUCE C had sold 3,000 shares from its account. In a trade valued at $479,590, the Chairman & CEO traded Jazz Pharmaceuticals plc shares for $159.86 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $53.13 million.

As published in a research note from Goldman on December 09, 2022, Jazz Pharmaceuticals plc [JAZZ] has been rated up from a Neutral to a Buy and the price target has been revised to $190 from $192. This represents a 24.03% premium over Thursday’s closing price. Analysts at UBS started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of April 06, 2022, Goldman has decreased its “Buy” rating to a “Neutral” for JAZZ.

Analyzing JAZZ Stock Performance

On Thursday, Jazz Pharmaceuticals plc [NASDAQ: JAZZ] rose 2.73% to $144.34. The stock’s lowest price that day was $140.23, but it reached a high of $145.6942 in the same session. During the last five days, there has been a drop of approximately -1.27%. Over the course of the year, Jazz Pharmaceuticals plc shares have dropped approximately -9.40%. Shares of the company reached a 52-week high of $160.96 on 01/03/23 and a 52-week low of $139.43 on 03/01/23. A 50-day SMA is recorded $153.20, while a 200-day SMA reached $149.91. Nevertheless, trading volume fell to 1.31 million shares from 1.04 million shares the previous day.

Support And Resistance Levels for Jazz Pharmaceuticals plc (JAZZ)

According to the 24-hour chart, there is a support level at 139.21, which, if violated, would cause prices to drop to 137.91. In the upper region, resistance lies at 142.03. The next price resistance is at 143.55. RSI (Relative Strength Index) is 40.69 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.19, which suggests the price will decrease in the coming days. Percent R is at 64.28%, indicating low price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Jazz Pharmaceuticals plc subject to short interest?

Stocks of Jazz Pharmaceuticals plc saw a sharp steep in short interest on Jan 30, 2023 dropping by -0.12 million shares to 2.58 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 2.7 million shares. A decline of -4.65% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.65 of the overall float, the days-to-cover ratio (short ratio) decline to 5.65.

Which companies own the most shares of Jazz Pharmaceuticals plc (JAZZ)?

According to The Vanguard Group, Inc. filings, the company currently owns 5,911,765 shares, which is about 9.39% of the total JAZZ shares outstanding. The investor’s shares have appreciated by 156,691 from its previous 13-F filing of 5755074.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $843,357,648. JPMorgan Investment Management, I reduced a -16.38% interest valued at $380.19 million while SSgA Funds Management, Inc. purchased a 15,476 stake. A total of 294,917 shares of Jazz Pharmaceuticals plc were bought by LSV Asset Management during the quarter, and -37,592 were sold by Wellington Management Co. LLP. In its current portfolio, Renaissance Technologies LLC holds 1,290,015 shares valued at $202.09 million.

In terms of Jazz Pharmaceuticals plc share price expectations, FactSet research, analysts set an average price target of $204.93 in the next 12 months, up nearly 44.47% from the previous closing price of $140.51. Analysts anticipate Jazz Pharmaceuticals plc stock to reach $240.00 by 2023, with the lowest price target being $180.00. In spite of this, 15 analysts ranked Jazz Pharmaceuticals plc stock as a Buy at the end of 2023. On October 07, 2021, Jefferies assigned a price target of “a Buy” to the stock and resumed coverage with a $172.


Please enter your comment!
Please enter your name here